BioPhausia AB Sells Generics Business

Medivir subsidiary, BioPhausia, has reached an agreement to sell its generics business, BMM Pharma, to Bluefish Pharmaceuticals for $4.1 million plus inventories valued at approximately $1.9 million. BMM Pharma’s staff will not transfer in the acquisition. Medivir is a research-based specialty pharmaceutical company focusing on infectious diseases.

“This deal is a natural last step in the concentration and focus of BioPhausia’s business, which began about a year ago. We will now be focusing on the ongoing commercial development of our Proprietary Products and Parallel Imported Products,” said Maris Hartmanis, chief executive office of BioPhausia.